Funding for this research was provided by:
national institutes of health (UL1TR001442-061)
astellas pharma us
Received: 18 June 2021
Accepted: 30 June 2021
First Online: 16 July 2021
: JP has received personal fees from Gilead Sciences and Pfizer, research funding from MSD and is stoke holder of AbbVie Inc and Novo Nordisk. JW reports grants and personal fees from Gilead and Pfizer: investigator-initiated grants, personal fees and also on-financial support from MSD. DRG reports an unconditional grant from Correvio Italia and a grant for his institution by Pfizer Inc. KL received consultancy fees from SMB Laboratories Brussels, MSD and Gilead, travel support from Pfizer, speaker fees from FUJIFILM WAKO, Pfizer and Gilead and a service fee from Thermo fisher Scientific. MH received research funding from Gilead Sciences, Astellas, Scynexis, F2G and Pfizer.
: The study protocol and all study-related procedures were approved by the Medical University of Graz (EC #32–296 ex 19/20) and the other participating centers which all followed the local ethical requirements.
Free to read: This content has been made available to all.